[Editorial in response to the article by D. Cechurová et al.: "Economic aspects of the diabetic foot syndrome"].

A Jirkovská

Vnitr Lek 2003, 49(6):439-441

[A few comments on primary pulmonary hypertension. An editorial on the review article "Primary pulmonary hypertension--aspects of diagnosis and therapy" by I. Rihácek, M. Soucek, T. Kára, P. Frána, M. Orban].

S Janousek, D Stratil

Vnitr Lek 2003, 49(6):442-446

[Comment on the article "Pharmacotherapy of pain in rheumatic disease"].

P Horák

Vnitr Lek 2003, 49(6):447-448

[Celiac disease--gluten enteropathy].

M Lukás

Vnitr Lek 2003, 49(6):449-451

[Remarks on the comments regarding clinical recommendations for diagnosis and therapy of community-acquired pneumonia by Prof. Kolka].

J Skricková

Vnitr Lek 2003, 49(6):452

[Economic aspects of the diabetic foot syndrome].

D Cechurová, S Lacigová, Z Rusavý, N Horáková, Z Jankovec, M Zourek

Vnitr Lek 2003, 49(6):453-456

UNLABELLED: The diabetic foot is one of the most expensive complications of diabetes mellitus.AIMS: To determine the direct costs of both inpatient and outpatient care of diabetic foot provided in Diabetic Centre University Hospital in Plzen.METHODS: 42 patients with diabetic ulcers (45% neuropathic, 26% ischaemic and 29% mixed) who have attended the podiatric surgery from January to June 2000 were randomly selected. SUBJECT CHARACTERISTICS: 4 patients with type 1 diabetes, 38 patients with type 2 diabetes, mean of age 63 years (37-81), mean of duration of diabetes 17 years (1-31), mean of duration of diabetic ulcers 37 months (1-168) ulcers....

[Calculation of the costs of drugs, medical materials, certain medical procedures and social services for patients with diabetic foot syndrome].

L Brunerová, M Anděl

Vnitr Lek 2003, 49(6):457-464

The aim of this study was to analyse the direct costs of some components of primary, secondary and tertiary prevention of the diabetic foot syndrome (cost of illness study). Information considering the costs of prevention and therapy of the diabetic foot and costs following after amputation in diabetic patients is available from international economical trials but is almost missing in the Czech Republic. The economical assessment of the most important mean of primary prevention/which is regular dispensarisation and preventive care for diabetic patients in risk of diabetic foot syndrome/is very problematic. The costs of primary prevention were calculated...

[Celiac sprue (review)].

P Fric

Vnitr Lek 2003, 49(6):465-473

Celiac sprue may be defined as a model autoimmune disease with known trigger (gluten), a tight genetic linkage (with HLA-DQ2 and HLA-DQ8) and a specific humoral autoimmune response (autoantibodies to tissue transglutaminase, tTG). Gliadin peptides are repeatedly presented to HLA-DQ2 and HLA-DQ8 positive cells and induce an immune response in small-intestinal mucosa. tTG is a specific endomysial autoantigen released during cellular stress and by deamidation of gliadin peptides as well as by binding with them facilitates their interaction with HLA-DQ2 and HLA-DQ8 cells. CS is the consequence of an inappropriate by T-cells mediated immune reaction to...

[Celiac disease--a severe disease].

L Prokopová

Vnitr Lek 2003, 49(6):474-481

Celiac disease (Celiacal sprue = gluten-sensitive enteropathy = netropic sprue) is the all-life genetically determined autoimmune disease with permanent intolerance to gluten, which damages the intestinal mucous membrane and alterates the immune system. The atrophy and typical inflammatory changes of mucous membrane results in malabsorption with diarrhea, general weakness, anemia and weight loss. The clinical picture of celiac disease is considerably heterologous. Only 20-30% of patients suffer from active-classical form of the disease. Non-diagnosed, inactive forms of the disease form 70-80% of cases of celiac disease in adult individuals. The therapy...

[Primary pulmonary hypertension--aspects of diagnosis and therapy].

I Rihácek, M Soucek, T Kára, P Frána, M Orban

Vnitr Lek 2003, 49(6):482-489

Primary Lung Hypertension is a serious disease of unknown cause. Various genetic, vasoconstriction, proliferation and procoagulation factor participate in etiology and pathogenesis. In establishing the diagnosis it is necessary to exclude secondary, particularly embolic cause of pulmonary hypertension. There are diseases with associated primary pulmonary hypertension. Present therapy improves symptoms of the disease, three years after the diagnosis is established, 75% of patients survive. In the therapy of primary pulmonary hypertension, the recommended drugs are calcium channel blockers, epoprostenol, oxygen therapy and anticoagulant drugs. The new,...

[Pharmacotherapy of pain in rheumatic disease].

S Alusík, K Trnavský

Vnitr Lek 2003, 49(6):490-495

The authors of this article discuss the pharmacotherapy of pain control in patients with rheumatic diseases, and they describe the relevant groups of drugs available, including their adverse events. They focus on non-steroidal antirheumatic drugs, selectice cyclooxygenase-2 inhibitors (coxibs) in particular. They summarise the experience with use of coxibs so far, and also report on drugs soon to be marketed in our country.

[Comments on current clinical recommendations for diagnosis and therapy of community-acquired pneumonia].

V Kolek

Vnitr Lek 2003, 49(6):496-501

[Consensus statement regarding indications for Leiden (FVL-factor V Leiden) mutation determination when recommending combined hormonal contraception or hormone replacement therapy].

D Cibula, J Kvasnicka, P Salaj, Z Vorlová, V Unzeitig, J Zivný

Vnitr Lek 2003, 49(6):502

[Comments on the article by Mydlíka et al, on the treatment of ethylene glycol poisoning].

Viktor Rosival

Vnitr Lek 2003, 49(6):505